The results from two previous Phase I trial demonstrated that the drug was safe and well tolerated when administered in healthy volunteers.
NI-0801 is a fully human monoclonal antibody that neutrilizes CXCL10/Interferon-gamma-inducible protein-10 (IP-10) chemokine.
Principal investigator of the PoC study David Adams said the therapeutic approach of neutralizing CXCL10/IP-10 with NI-0801 will potentially offer, for the first time, great benefits to the large and therapeutically ill-served PBC patient population.